Geovax Labs Inc Trading Halted, News Pending
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 10 2026
0mins
Geovax Labs Inc trading halted, news pending
Get Free Real-Time Notifications for Any Stock
Monitor tickers like GOVX with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on GOVX
Wall Street analysts forecast GOVX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GOVX is 12.00 USD with a low forecast of 10.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.840
Low
10.00
Averages
12.00
High
14.00
Current: 2.840
Low
10.00
Averages
12.00
High
14.00
About GOVX
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. Its lead clinical program is GEO-CM04S1, a COVID-19 vaccine, which is in three phase II clinical trials, being evaluated as a primary vaccine for immunocompromised patients, such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient; a booster vaccine in patients with chronic lymphocytic leukemia (CLL); and a COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology, the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin, having completed a multicenter Phase I/II clinical trial for advanced head and neck cancers. It is developing GEO-MVA, a vaccine targeting Mpox and smallpox. Its other product candidates include GEO-EM01-Z, GEO-EM01-S, GEO-MM01, GEO-ZM02 and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tilray Brands Reports Q2 Earnings Beat, Shares Surge 7.3%
- Earnings Beat: Tilray Brands reported Q2 earnings of $0.01 per share, surpassing the market expectation of a $0.20 loss, indicating a significant improvement in profitability that boosts investor confidence.
- Revenue Growth: The company achieved quarterly revenue of $217.51 million, exceeding the consensus estimate of $210.95 million, demonstrating success in market demand and sales strategies, which further solidifies its market position.
- Stock Price Surge: Following the positive earnings report, Tilray Brands' shares rose 7.3% to $9.80 in pre-market trading, reflecting investor optimism about the company's future growth potential.
- Positive Market Reaction: The strong performance post-earnings release may attract more investor attention, enhancing the company's appeal in a competitive market landscape.
Continue Reading
Dow Rises by More Than 200 Points; Conagra Stock Declines Following Q2 Earnings Report
U.S. Stock Market Performance: U.S. stocks rose this morning, with the Dow Jones gaining over 200 points, while the NASDAQ and S&P 500 also saw increases of 1.03% and 0.73%, respectively.
Sector Movements: Information technology shares increased by 1.6%, while real estate stocks experienced a slight decline of 0.1%.
Notable Stock Movements: Conagra Brands Inc. shares fell over 4% despite beating earnings estimates, while Autozi Internet Technology's shares surged 85% following a significant investment announcement.
Global Market Trends: European and Asian markets closed higher, with notable gains in major indices, and U.S. existing home sales rose by 0.5% in November.
Continue Reading